The mid-term success rate of intrahepatic cholangiocellular carcinoma can now be expressed in terms of postoperative 5-year survival rate, and the postoperative 5-year survival rate of mid-term intrahepatic cholangiocellular carcinoma is only 5%~10%. Intrahepatic cholangiocellular carcinoma is a malignant tumor with high degree of malignancy, and the growth of cancerous tissues needs a large amount of nutrients from the organism. Patients with intrahepatic cholangiocellular carcinoma mostly have no obvious symptoms in the early stage, and with the progression of the disease, they may have symptoms such as unexplained fatigue, loss of appetite, weight loss, abdominal pain, abdominal distension and so on. If the location is far away from big blood vessels, bold tube and other important structures, the patient is young and has no chronic diseases such as hypertension, diabetes, cerebrovascular disease, etc., and tolerates the surgery well, the success rate of the surgery is high, and auxiliary treatments such as radiochemotherapy and targeted therapy can be carried out. However, even so, the survival rate of intrahepatic cholangiocarcinoma in the middle stage is only 5%~10% in the postoperative period of 5 years. It is suggested that patients should go to the hospital in time to avoid delaying the condition and causing other damages.